214 related articles for article (PubMed ID: 25142233)
1. Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer.
Mahdavi M; Keyhanfar M; Jafarian A; Mohabatkar H; Rabbani M
Tumour Biol; 2014 Dec; 35(12):12049-57. PubMed ID: 25142233
[TBL] [Abstract][Full Text] [Related]
2. In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines.
Manijeh M; Mehrnaz K; Violaine M; Hassan M; Abbas J; Mohammad R
Asian Pac J Cancer Prev; 2013; 14(10):5973-81. PubMed ID: 24289611
[TBL] [Abstract][Full Text] [Related]
3. Linear and conformational B cell epitope prediction of the HER 2 ECD-subdomain III by in silico methods.
Mahdavi M; Mohabatkar H; Keyhanfar M; Dehkordi AJ; Rabbani M
Asian Pac J Cancer Prev; 2012; 13(7):3053-9. PubMed ID: 22994709
[TBL] [Abstract][Full Text] [Related]
4. Production and Characterization of New Anti-HER2 Monoclonal Antibodies.
Mahdavi M; Keyhanfar M; Jafarian A; Mohabatkar H; Rabbani M
Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):213-21. PubMed ID: 26090600
[TBL] [Abstract][Full Text] [Related]
5. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.
Ceran C; Cokol M; Cingoz S; Tasan I; Ozturk M; Yagci T
BMC Cancer; 2012 Oct; 12():450. PubMed ID: 23033967
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of new HER2 peptide vaccination based on B cell epitope.
Miyako H; Kametani Y; Katano I; Ito R; Tsuda B; Furukawa A; Saito Y; Ishikawa D; Ogino K; Sasaki S; Imai K; Habu S; Makuuchi H; Tokuda Y
Anticancer Res; 2011 Oct; 31(10):3361-8. PubMed ID: 21965747
[TBL] [Abstract][Full Text] [Related]
7. Antibody Response to Human Extracellular HER2 Subdomain Proteins in Mice.
Sadri-Ardalani F; Ahmadi M; Hemmati A; Emami S; Farid S; Amiri MM; Jeddi-Tehrani M; Shabani M; Shokri F
Iran J Immunol; 2017 Jun; 14(2):99-110. PubMed ID: 28630381
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of evolutionarily conserved motifs of epidermal growth factor receptor 2 (HER2) predicts novel potential therapeutic epitopes.
Deng X; Zheng X; Yang H; Moreira JM; Brünner N; Christensen H
PLoS One; 2014; 9(9):e106448. PubMed ID: 25192037
[TBL] [Abstract][Full Text] [Related]
9. Induction of protective anti-CTL epitope responses against HER-2-positive breast cancer based on multivalent T7 phage nanoparticles.
Pouyanfard S; Bamdad T; Hashemi H; Bandehpour M; Kazemi B
PLoS One; 2012; 7(11):e49539. PubMed ID: 23166703
[TBL] [Abstract][Full Text] [Related]
10. Induction of virus-specific neutralizing immune response against West Nile and Japanese encephalitis viruses by chimeric peptides representing T-helper and B-cell epitopes.
Gangwar RS; Shil P; Sapkal GN; Khan SA; Gore MM
Virus Res; 2012 Jan; 163(1):40-50. PubMed ID: 21889960
[TBL] [Abstract][Full Text] [Related]
11. Immune response of mice transgenic for human histocompatibility leukocyte Antigen-DR to human thyrotropin receptor-extracellular domain.
Inaba H; Pan D; Shin YH; Martin W; Buchman G; De Groot LJ
Thyroid; 2009 Nov; 19(11):1271-80. PubMed ID: 19725778
[TBL] [Abstract][Full Text] [Related]
12. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
Kaumaya PT; Foy KC; Garrett J; Rawale SV; Vicari D; Thurmond JM; Lamb T; Mani A; Kane Y; Balint CR; Chalupa D; Otterson GA; Shapiro CL; Fowler JM; Grever MR; Bekaii-Saab TS; Carson WE
J Clin Oncol; 2009 Nov; 27(31):5270-7. PubMed ID: 19752336
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu.
Jasinska J; Wagner S; Radauer C; Sedivy R; Brodowicz T; Wiltschke C; Breiteneder H; Pehamberger H; Scheiner O; Wiedermann U; Zielinski CC
Int J Cancer; 2003 Dec; 107(6):976-83. PubMed ID: 14601058
[TBL] [Abstract][Full Text] [Related]
14. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses.
Li S; Peng L; Zhao W; Zhong H; Zhang F; Yan Z; Cao H
Vaccine; 2011 May; 29(20):3695-702. PubMed ID: 21419774
[TBL] [Abstract][Full Text] [Related]
15. Polyepitope protein incorporated the HIV-1 mimotope recognized by monoclonal antibody 2G12.
Karpenko LI; Scherbakova NS; Chikaev AN; Tumanova OY; Lebedev LR; Shalamova LA; Pyankova OG; Ryzhikov AB; Ilyichev AA
Mol Immunol; 2012 Apr; 50(4):193-9. PubMed ID: 22341130
[TBL] [Abstract][Full Text] [Related]
16. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.
Dakappagari NK; Douglas DB; Triozzi PL; Stevens VC; Kaumaya PT
Cancer Res; 2000 Jul; 60(14):3782-9. PubMed ID: 10919651
[TBL] [Abstract][Full Text] [Related]
17. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu.
Garrett JT; Rawale S; Allen SD; Phillips G; Forni G; Morris JC; Kaumaya PT
J Immunol; 2007 Jun; 178(11):7120-31. PubMed ID: 17513761
[TBL] [Abstract][Full Text] [Related]
18. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
[TBL] [Abstract][Full Text] [Related]
19. Identifying B and T cell epitopes and studying humoral, mucosal and cellular immune responses of peptides derived from V antigen of Yersinia pestis.
Khan AA; Babu JP; Gupta G; Rao DN
Vaccine; 2008 Jan; 26(3):316-32. PubMed ID: 18096277
[TBL] [Abstract][Full Text] [Related]
20. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Hu S; Zhu Z; Li L; Chang L; Li W; Cheng L; Teng M; Liu J
Proteins; 2008 Feb; 70(3):938-49. PubMed ID: 17847085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
